The development of interventions to slow or halt the progression of Parkinson's disease
remains a priority for patients and researchers alike. To date, no agents have been shown to …

Parkinson's disease prevalence is rapidly increasing in an aging global population. With this
increase comes exponentially rising social and economic costs, emphasizing the immediate …

Dopamine is a prototypical neuromodulator that controls circuit function through G protein-
coupled receptor signalling. Neuromodulators are volume transmitters, with release followed …

The large number of ion channels found in all nervous systems poses fundamental
questions concerning how the characteristic intrinsic properties of single neurons are …

Schizophrenia is a debilitating psychiatric condition often associated with poor quality of life
and decreased life expectancy. Lack of progress in improving treatment outcomes has been …

Intracellular α-synuclein (α-syn)-rich protein aggregates called Lewy pathology (LP) and
neuronal death are commonly found in the brains of patients with clinical Parkinson disease …

How do neurons match generation of adenosine triphosphate by mitochondria to the
bioenergetic demands of regenerative activity? Although the subject of speculation, this …

Parkinson's disease (PD) is the second most common neurodegenerative disease. About
2% of the population above the age of 60 is affected by the disease. The pathological …

New discoveries providing insights into mitochondrial bioenergetics, their dynamic
interactions as well as their role in cellular homeostasis have dramatically advanced our …

The cardinal motor symptoms of Parkinson's disease (PD) are caused by the death of
dopaminergic neurons in the substantia nigra pars compacta (SN c). Alpha‐synuclein …